Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo Controlled, Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy

NCT00726544 is registered in ClinicalTrials.gov with Archemix Corp. as lead sponsor.

NCT NCT00726544
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00726544 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo Controlled, Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy
Lead sponsor
Archemix Corp.
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2008
Completion date
March 31, 2011
Enrollment
100 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

thrombotic microangiopathy, thrombotic thrombocytopenic purpura